Harvey RD, Rubinstein WS, Ison G, et al. Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis. ASCO Annual Meeting 2019, abstract LBA108.
Tivozanib versus sorafenib als derde- of vierdelijnsbehandeling van gemetastaseerd niercelcarcinoom
mrt 2020 | Uro-oncologie